Stock Movements, FDA Clearances, Collaborations, and Agreements - Research Report on CytRx, Quidel, Repligen, Intrexon, and Acacia

Editor Note: For more information about this release, please scroll to bottom.

Jan 06, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 6, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting CytRx Corporation (NASDAQ: CYTR), Quidel Corp. (NASDAQ: QDEL), Repligen Corporation (NASDAQ: RGEN), Intrexon Corporation (NYSE: XON), and Acacia Research Corporation (NASDAQ: ACTG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

CytRx Corporation Research Report

On December 31, 2013, CytRx Corporation's (CytRx) stock went up by 8.29%, closing at $6.27. Over the past three-day trading period, the Company's stock increased significantly by 35.71%, compared to the Nasdaq Composite which went up by 0.23% during the same three-day trading period. The Full Research Report on CytRx Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1869_CYTR

Quidel Corp. Research Report

On December 30, 2013, Quidel Corp. (Quidel) announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to sell AmpliVue Group B Strep Assay, the Company's non-instrumented molecular diagnostic test that utilizes a novel amplification technology with an easy-to-use, hand-held device. Additionally, the Company stated that the AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification (HDA) with the Company's well-established expertise in lateral flow technology to detect Group B Streptococcus (GBS) from enriched broth cultures of specimens from antepartum women. Douglas Bryant, President and CEO of Quidel stated, "We are pleased to receive 510(k) clearance for our AmpliVue Group B Strep assay. We can now provide the hospital laboratories with another AmpliVue assay for fast, accurate infectious disease testing without the need for additional investments in expensive equipment." The Full Research Report on Quidel Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2c87_QDEL

Repligen Corporation Research Report

On December 31, 2013, Repligen Corporation's (Repligen) stock increased 6.65%, as it closed the day at $13.64. During the past three trading days, the Company's stock went up by 5.90%, compared to the Dow Jones Industrial Average which rose 0.59% over the same three-day trading period. The Full Research Report on Repligen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fdda_RGEN

Intrexon Corporation Research Report

On December 31, 2013, Intrexon Corporation (Intrexon), along with Agilis Biotherapeutics, LLC (Agilis Biotherapeutics), announced an Exclusive Channel Collaboration (ECC) for developing DNA-based therapeutics for Friedreich's ataxia (FRDA). According to the Company, Agilis and Intrexon expect DNA-based therapeutics to provide the ability to target underlying disease mechanisms with precision using tightly-controlled gene therapies for patients with FRDA. Commenting on the collaboration, Samuel Broder, M.D., Senior Vice President of Intrexon's Health Sector and former Director of the National Cancer Institute, stated, "FRDA causes heart failure and progressive neurological deterioration, which in turn cause suffering and premature deaths. The goal of this collaboration is to harness Intrexon's proprietary technologies in synthetic DNA, as well as our expertise in molecular, protein, and cellular engineering, to benefit patients with this very serious disorder." The Full Research Report on Intrexon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cb5c_XON

Acacia Research Corporation Research Report

On December 31, 2013, Acacia Research Corporation (Acacia) announced that the Company's Bolt MRI Technologies LLC subsidiary has entered into an agreement with Fonar Corporation. According to the Company, this agreement resolves litigation that was pending in the United States District Court for the Eastern District of New York. In a separate release on the same date, the Company announced that its Brandywine Communications Technologies LLC subsidiary has entered into a settlement and patent license agreement with Alcatel-Lucent USA, Inc., resolving litigation that was pending in the United States District Court for the District of Delaware. The Full Research Report on Acacia Research Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/78f8_ACTG

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner